当前位置: X-MOL 学术Nat. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.
Nature Medicine ( IF 82.9 ) Pub Date : 2017-09-04 , DOI: 10.1038/nm.4396
Chad E Mire 1, 2 , Robert W Cross 1, 2 , Joan B Geisbert 1, 2 , Viktoriya Borisevich 1, 2 , Krystle N Agans 1, 2 , Daniel J Deer 1, 2 , Megan L Heinrich 3 , Megan M Rowland 3 , Augustine Goba 4, 5 , Mambu Momoh 4, 5, 6 , Mathew L Boisen 3 , Donald S Grant 4, 5 , Mohamed Fullah 4, 5 , Sheik Humarr Khan 4, 5 , Karla A Fenton 1, 2 , James E Robinson 7 , Luis M Branco 3 , Robert F Garry 3, 8, 9 , Thomas W Geisbert 1, 2
Affiliation  

There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.

中文翻译:

人类单克隆抗体疗法可保护非人类灵长类动物免受晚期拉沙热的侵害。

目前尚无批准的拉萨热疗法,这种疗法在最近被埃博拉病毒肆虐的西非地区普遍存在。在这里,我们显示了与拉萨病毒所有四个进化枝的糖蛋白交叉反应的人单克隆抗体的组合能够在疾病的晚期(包括攻击后长达8天)开始治疗时,挽救100%的食蟹猕猴。 。
更新日期:2017-09-07
down
wechat
bug